PBS updates

APO-Topiramate (Topiramate)

topiramate 50 mg tablet, 60 · ORAL · PBS code 13913G

STREAMLINED

What it costs

AU$5.26 PBS-determined price per 120 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2024-03-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Seizures


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

Patient must have focal onset seizures; or

Patient must have primary generalised tonic-clonic seizures; or

Patient must have seizures of the Lennox-Gastaut syndrome; AND

The condition must have failed to be controlled satisfactorily by at least one other antiseizure medication; AND

Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Migraine


The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND

The treatment must be for prophylaxis; AND

Patient must have experienced an average of 3 or more migraines per month over a period of at least 6 months; AND

Patient must have a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; or

Patient must have experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker; AND

Patient must have a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; or

Patient must have experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.

Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated.

Sponsor: Apotex Pty Ltd ABN 52 096 916 148

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.